Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer’s Treatment

Author(s): Bijo Mathew*

Journal Name: Combinatorial Chemistry & High Throughput Screening
Accelerated Technologies for Biotechnology, Bioassays, Medicinal Chemistry and Natural Products Research

Volume 23 , Issue 9 , 2020

Become EABM
Become Reviewer
Call for Editor


Multi-functional design of ligands emerged as a new drug design paradigm of Alzheimer’s disease (AD). Given the complexity of AD, the molecules showing dual inhibition of monoamine oxidase (MAO) and acetylcholinesterase (AChE) with neuroprotective properties could prevent the progressive neural degeneration effectively. Numerous studies documented that chalcone is a privileged structural framework for the inhibition of both MAO and AChE. The recent studies suggested that the development of chalcone candidates endowed with pharmacophores of FDA approved drugs may become an active molecules in the field of current AD research. The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD.

Keywords: Chalcones, pharmacophore, monoamine oxidase, acetylcholinesterase, flurbiprofen, rivastigmine.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 22 December, 2020
Page: [842 - 846]
Pages: 5
DOI: 10.2174/1386207323999200728122627
Price: $65

Article Metrics

PDF: 27